Model‐Informed Drug Development in Pediatric Dose Selection. (29th June 2021)

• Record Type: Journal Article
• Authors: Bi, Youwei; Liu, Jiang; Li, Fang; Yu, Jingyu; Bhattaram, Atul; Bewernitz, Michael; Li, Ruo‐jing; Ahn, Jihye; Earp, Justin; Ma, Lian; Zhuang, Luning; Yang, Yuching; Zhang, Xinyuan; Zhu, Hao; Wang, Yaning
• Other Names: Burckart Gilbert J. guestEditor.; van den Anker John N. guestEditor.
• Is Part Of: Journal of clinical pharmacology. Volume 61(2021)Supplement 1
• Page Start: S60
• Page End: S69
• Publication Date: 2021-06-29
• Subjects: dose selection and optimization -- leveraging knowledge -- model‐informed drug development -- pediatric drug development -- pediatric dose selection -- pediatric ontogeny; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1848
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Model‐informed drug development (MIDD) has been a powerful and efficient tool applied widely in pediatric drug development due to its ability to integrate and leverage existing knowledge from different sources to narrow knowledge gaps. The dose selection is the most common MIDD application in regulatory submission related to pediatric drug development. This article aims to give an overview of the 3 broad categories of use of MIDD in pediatric dose selection: leveraging from adults to pediatric patients, leveraging from animals to pediatric patients, and integrating mechanism in infants and neonates. Population pharmacokinetic analyses with allometric scaling can reasonably predict the clearance in pediatric patients aged >5 years. A mechanistic‐based approach, such as physiologically based pharmacokinetic accounting for ontogeny, or an allometric model with age‐dependent exponent, can be applied to select the dose in pediatric patients aged ≤2 years. The exposure‐response relationship from adults or from other drugs in the same class may be useful in aiding the pediatric dose selection and benefit‐risk assessment. Increasing application and understanding of use of MIDD have contributed greatly to several policy developments in the pediatric field. With the increasing efforts of MIDD under the Prescription Drug User Fee Act VI, bigger impacts of MIDD approaches in pediatric dose selection can be expected. Due to the complexity of model‐based analyses, early engagement between drug developers and regulatory agencies to discuss MIDD issues is highly encouraged, as it is expected to increase the efficiency and reduce the uncertainty.